Acurx Pharmaceuticals, Inc.
ACXP
$4.08
$0.225.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.88M | 7.43M | 8.70M | 9.92M | 10.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.02M | 11.88M | 14.10M | 16.44M | 16.73M |
| Operating Income | -10.02M | -11.88M | -14.10M | -16.44M | -16.73M |
| Income Before Tax | -10.00M | -11.87M | -14.10M | -16.44M | -16.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.00 | -11.87 | -14.10 | -16.44 | -16.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.00M | -11.87M | -14.10M | -16.44M | -16.73M |
| EBIT | -10.02M | -11.88M | -14.10M | -16.44M | -16.73M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -10.77 | -14.09 | -17.60 | -21.71 | -23.05 |
| Normalized Basic EPS | -6.73 | -8.81 | -11.00 | -13.57 | -14.41 |
| EPS Diluted | -10.77 | -14.09 | -17.60 | -21.71 | -23.05 |
| Normalized Diluted EPS | -6.73 | -8.81 | -11.00 | -13.57 | -14.41 |
| Average Basic Shares Outstanding | 3.86M | 3.46M | 3.23M | 3.08M | 2.91M |
| Average Diluted Shares Outstanding | 3.86M | 3.46M | 3.23M | 3.08M | 2.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |